Drug Price Battle Now Bipartisan; Should Pharma Fret?
This article was originally published in Scrip
Executive Summary
Drug companies, particularly Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG, got a double punch from Capitol Hill on Nov. 4 when lawmakers from the House and the Senate upped their pressure on drug pricing – with a group of Democrats forming a new task force focused on combating "skyrocketing" costs of medicines and two senators turning the battle into a bipartisan fight by opening a new investigation and revealing plans for a hearing in December on the matter.